Trial ID 20248 | Maryland Oncology Hematology Trial ID 20248 – Maryland Oncology Hematology

Trial ID 20248

Trial Information - Phase III

A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer

Protocol ID: 67652000PCR3002

Sponsor: Janssen Research & Development, LLC

Status: OPEN TO ENROLLMENT

Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at 877-664-7724

Disease Types

Prostate

Investigator

Tiwarri MD, Deepnarayan

Status

OPEN TO ENROLLMENT

Sponsor

Janssen Research & Development, LLC

Quality Care Close to Home


View our locations on map!

Sign Up Today For Our E-Newsletter

  • This field is for validation purposes and should be left unchanged.
United in Healing with The US Oncology Network - Maryland Oncology Hematology